800
Participants
Start Date
April 30, 2025
Primary Completion Date
June 30, 2029
Study Completion Date
November 30, 2029
Alectinib
"Participants will have received alectinib adjuvant treatment for resected stage II-IIIB ALK-positive NSCLC in routine clinical practice.~NOTE: No intervention will be provided in this study as the study is observational."
RECRUITING
Hebei Medical University Fourth Hospital, Shijiazhuang
RECRUITING
Peking University First Hospital, Beijing
ACTIVE_NOT_RECRUITING
Xuanwu Hospital, Capital Medical University, Beijing
RECRUITING
Shanghai Pulmonary Hospital, Shanghai
RECRUITING
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing
RECRUITING
Wuxi People's Hospital, Wuxi
RECRUITING
Shandong Provincial Hospital, Jinan
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Taizhou Hospital of Zhejiang Province, Taizhou
RECRUITING
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan
RECRUITING
Henan Provincial Chest Hospital, Zhengzhou
RECRUITING
The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou
RECRUITING
Jiangmen Central Hospital, Jiangmen
RECRUITING
Affiliated Hospital of Zunyi Medical University, Zunyi
RECRUITING
Lanzhou University Second Hospital, Lanzhou
RECRUITING
General Hospital of Ningxia Medical University, Yinchuan
RECRUITING
Shanxi Provincial Cancer Hospital, Taiyuan
RECRUITING
Chest disease hospital of Tianjin City, Tianjin
Hoffmann-La Roche
INDUSTRY